These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 14679018)

  • 41. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy.
    Rabien A; Burkhardt M; Jung M; Fritzsche F; Ringsdorf M; Schicktanz H; Loening SA; Kristiansen G; Jung K
    Eur Urol; 2007 May; 51(5):1259-66. PubMed ID: 16806661
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review.
    Qiu YQ; Leuschner I; Braun PM
    Asian J Androl; 2008 Nov; 10(6):855-63. PubMed ID: 18958349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic significance of thymidylate synthase expression in patients with prostate cancer undergoing radical prostatectomy.
    Li Y; Mizutani Y; Shiraishi T; Okihara K; Ukimura O; Kawauchi A; Nonomura N; Fukushima M; Sakai T; Miki T
    Urology; 2007 May; 69(5):988-95. PubMed ID: 17482957
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role.
    Miyata Y; Iwata T; Maruta S; Kanda S; Nishikido M; Koga S; Kanetake H
    Eur Urol; 2007 Sep; 52(3):791-7. PubMed ID: 17207914
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
    Rubin MA; Bismar TA; Andrén O; Mucci L; Kim R; Shen R; Ghosh D; Wei JT; Chinnaiyan AM; Adami HO; Kantoff PW; Johansson JE
    Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1424-32. PubMed ID: 15941951
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic relevance of increased Rac GTPase expression in prostate carcinomas.
    Engers R; Ziegler S; Mueller M; Walter A; Willers R; Gabbert HE
    Endocr Relat Cancer; 2007 Jun; 14(2):245-56. PubMed ID: 17639041
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy.
    Xu C; Jung M; Burkhardt M; Stephan C; Schnorr D; Loening S; Jung K; Dietel M; Kristiansen G
    Prostate; 2005 Feb; 62(3):224-32. PubMed ID: 15389793
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
    Miyake H; Sakai I; Harada K; Eto H; Hara I
    Hinyokika Kiyo; 2005 Apr; 51(4):241-6. PubMed ID: 15912782
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy.
    Rosenbaum E; Hoque MO; Cohen Y; Zahurak M; Eisenberger MA; Epstein JI; Partin AW; Sidransky D
    Clin Cancer Res; 2005 Dec; 11(23):8321-5. PubMed ID: 16322291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Obesity and survival after radical prostatectomy: A 10-year prospective cohort study.
    Siddiqui SA; Inman BA; Sengupta S; Slezak JM; Bergstralh EJ; Leibovich BC; Zincke H; Blute ML
    Cancer; 2006 Aug; 107(3):521-9. PubMed ID: 16773619
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The outcome of patients with pathological Gleason score >or=8 prostate cancer after radical prostatectomy.
    Rodriguez-Covarrubias F; Larre S; De La Taille A; Abbou CC; Salomon L
    BJU Int; 2008 Feb; 101(3):305-7. PubMed ID: 17941921
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ki-67 in screen-detected, low-grade, low-stage prostate cancer, relation to prostate-specific antigen doubling time, Gleason score and prostate-specific antigen relapse after radical prostatectomy.
    Khatami A; Hugosson J; Wang W; Damber JE
    Scand J Urol Nephrol; 2009; 43(1):12-8. PubMed ID: 18949633
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epithelial MMP-2 expression correlates with worse prognosis in pancreatic cancer.
    Juuti A; Lundin J; Nordling S; Louhimo J; Haglund C
    Oncology; 2006; 71(1-2):61-8. PubMed ID: 17377415
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immunological microenvironment in prostate cancer: high mast cell densities are associated with favorable tumor characteristics and good prognosis.
    Fleischmann A; Schlomm T; Köllermann J; Sekulic N; Huland H; Mirlacher M; Sauter G; Simon R; Erbersdobler A
    Prostate; 2009 Jun; 69(9):976-81. PubMed ID: 19274666
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of preoperative serum cell-free circulating DNA in men with prostate cancer undergoing radical prostatectomy.
    Bastian PJ; Palapattu GS; Yegnasubramanian S; Lin X; Rogers CG; Mangold LA; Trock B; Eisenberger M; Partin AW; Nelson WG
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5361-7. PubMed ID: 17875764
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Prognostic significance of neuroendocrine expression in lymph node-positive prostate cancer.
    Quek ML; Daneshmand S; Rodrigo S; Cai J; Dorff TB; Groshen S; Skinner DG; Lieskovsky G; Pinski J
    Urology; 2006 Jun; 67(6):1247-52. PubMed ID: 16697447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic factors in lymph node-positive prostate cancer.
    Hofer MD; Kuefer R; Huang W; Li H; Bismar TA; Perner S; Hautmann RE; Sanda MG; Gschwend JE; Rubin MA
    Urology; 2006 May; 67(5):1016-21. PubMed ID: 16698361
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Analysis of NKX3.1 expression in prostate cancer tissues and correlation with clinicopathologic features.
    Aslan G; Irer B; Tuna B; Yorukoglu K; Saatcioglu F; Celebi I
    Pathol Res Pract; 2006; 202(2):93-8. PubMed ID: 16413692
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Tertiary Gleason pattern 5 is a powerful predictor of biochemical relapse in patients with Gleason score 7 prostatic adenocarcinoma.
    Hattab EM; Koch MO; Eble JN; Lin H; Cheng L
    J Urol; 2006 May; 175(5):1695-9; discussion 1699. PubMed ID: 16600733
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.